A marketing agency for research peptide companies, compliance first
Wealth Marketing AI is a marketing agency for US research peptide brands whose ads get rejected and accounts get restricted. We build compliant creative per SKU, pages that pass review, clean accounts and tracking. The fee is a flat $5,000 a month, month to month, and you fund the ad spend. We build nothing made to get around review.
Last updated
Twenty minutes. Bring your rejection history and your product list.
Is this for you, and is it not?
The second list is the one worth reading. A page that only sells tells you nothing you can use, and most of the enquiries we turn down are turned down for something on it.
Is this for you
- A US company selling research peptides for research use only from its own website.
- You are already advertising, or trying to, on Meta, Google, TikTok or Microsoft, and rejections or restrictions are costing you revenue or your own time.
- You publish purity, testing method and certificates of analysis, so the ads can be written out of facts rather than adjectives.
- Your catalogue has compounds beyond GLP-1s and PT-141.
- You want the ad account to survive, not the next trick to work once.
- A founder or head of growth who can sign off on every ad and page before it runs.
Is this not for you
- You want a way around platform review. Ask for one and we decline the engagement. We do not run those tactics and we do not describe them, even to criticise them.
- GLP-1 compounds or PT-141 are the only products worth advertising for you. They are off limits in everything we produce, whatever else the catalogue sells.
- You are a clinic, a telehealth service, a compounding pharmacy or a med spa selling to patients. Different rules, different agency.
- You sell explicitly for human use, or you want dosing and treatment claims in the ads.
- You want a guaranteed approval. Nobody can promise a platform decision and we will not pretend otherwise.
- You are not in the United States.
What you get, what it costs, and what you keep.
- Fee
- $5,000 a month, flat, in USD, invoiced monthly, month to month with no long tie-in.
- How it is paid
- Monthly, for services rendered. No percentage of revenue and no per-order fee. The platforms bill media to you inside your own accounts, so nothing routes through us and the billing history stays on your own business record.
- What we run
- A compliance-first creative system per SKU, landing pages built for review, ad account structure and hygiene, tracking that fires at the right step, a proper appeal when a compliant ad is wrongly flagged, and a one-page weekly report with a 20-minute call.
- What you do
- Supply the product facts and the photography, and sign off on every ad and page before it runs, and again on any change.
- What you own when it ends
- All of it. The creative, the landing pages, the tag container, the pixel and datasets, the ad account structure and the reporting are on your own domain and inside your own accounts, and they stay there.
- Off limits
- GLP-1 compounds and PT-141 in every ad and every page we produce, plus dosing, human-use, disease and before-and-after language. That is not negotiable.
- Approvals and volume
- Never promised. No one can guarantee a platform decision, and an account carrying prior violations carries that history into every review.
How long before anything happens?
| When | What happens |
|---|---|
| Days 1 to 7 | Access to the ad accounts, the business manager, the domain, the tag manager and the store. Rejection history pulled from every account. The risk check run on every live ad and page. Product list agreed with the off-limits SKUs removed. |
| Days 7 to 21 | Creative system built for the first SKUs. Landing pages drafted, reviewed by you, published. Account hygiene done. Tracking verified with a test order. First compliant ads submitted. |
| Days 21 to 45 | Review cycles. Rejections logged, root-caused and fixed in the system rather than one ad at a time. Appeals filed where an ad is compliant. The weekly report starts. |
| Days 45 to 90 | Scale what is approved and converting. New SKUs onto the same rules. Decide what to keep and what to stop. |
Plan two to three weeks from signed to live. A rebuilt page usually has to be reviewed again, so the launch is staged deliberately rather than submitted all at once.
Can you guarantee my ads get approved?
No. Nobody can guarantee a platform decision and anyone who says otherwise is guessing with your account. What we can do is remove the reasons ads get rejected, log the ones that are flagged anyway, fix the cause in the system rather than in one ad, and appeal properly when a compliant ad is wrongly refused.
Other agencies say they can get anything approved. Why can you not?
Ask them how. If the answer involves anything whose purpose is to get around review, that is the account you lose next quarter, and the loss usually takes the business manager with it. We make ads pass review on their own terms. The reviewer and the buyer see the same page, every time, with no exceptions.
Which products will you not advertise?
GLP-1 compounds and PT-141 are off limits in every ad and every page we produce, whatever else the catalogue sells. We also refuse dosing, human-use language, disease or treatment claims, and before-and-after framing. If those are the only products worth advertising for you, we are not a fit and we will say so on the call.
What does it cost, and am I tied in?
A flat $5,000 a month in USD, month to month, with no long contract and no setup fee. Ad spend is separate and you fund it directly inside accounts you own. There is no percentage of revenue and no per-order fee, so the invoice is the same whether a month is good or bad.
Who owns the accounts, the pages and the creative?
You do, throughout. The ad accounts, the business manager, the pixel and datasets, the landing pages on your own domain, the tag container and the reporting are yours. We hold access as a vendor for the engagement and you can remove it at any time. Nothing we build is held back as leverage.
We already have creative. Do we need you?
Possibly not. Run our ad rejection risk check on your existing copy and pages first. It runs in your browser, sends nothing anywhere and is free. If it flags nothing across your live ads and product pages, say so on the call and we will tell you honestly that you have a different problem.
Our account already has violations on it. Is it too late?
It is not automatically too late, but it is a real disadvantage and we will not pretend it is not. An account carrying prior violations carries that history into every review, so decisions come back harsher and slower. We audit the history first, fix the causes still live on your pages, and tell you if a clean start is the better option.
What do you actually send me every week?
One page, every week: spend, results, cost per result, ads submitted, ads approved, ads rejected and the policy reason for each, appeals outstanding, account status, and the one change we are making this week. A 20-minute call sits on top of it. It is readable in two minutes.
What we can name, and what we cannot.
We run paid acquisition for a research peptide brand today. The brand stays unnamed until it says otherwise, and no numbers are attached to it, on purpose. There are no client logos on this page because we are not free to put any there.
What we can show you is our own measurement. The Peptide Ad Review reads the public pages of research peptide storefronts against the phrase families Meta and Google name in their own published advertising policies, on a stated date, with the method published so anyone can repeat it.
- The Peptide Ad Review 2026: 411 US brands on the list, 334 readable, crawled 15 September 2026, scored on nine public ad-review signals.
- Can you advertise research peptides in 2026?: the platforms' own policy text quoted and linked, and why a research use only line does not save a page.
- The 9pm Test, the method: how we check, publicly and on a stated date, what a buyer meets after hours.
Sources and method
- Fees, terms and inclusions on this page are the published terms of Wealth Marketing AI as of September 17, 2026. The same terms are set out on the research peptide hub.
- Research method: the 9pm Test, a method created by Juan Camilo at Wealth Marketing AI, 2026. Every figure we publish from it carries its crawl date and its market.
Keep the account, and let the ads do the selling.
On the call we look at your rejection history, your catalogue, your pages and whether it is a fit. It ends with a yes, a no, or a booked next step, never a proposal that goes nowhere.